Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDennis KimFMFrancesco MannelliJGJosep F Nomdedeu Guinot

Discussion

Loading...

Member takes

Overview

Real-world data shows varied clinical outcomes in acute myeloid leukemia, indicating a need for improved MRD assessments.

Key Points

  • To establish contemporary benchmarks for clinical outcomes and measurable residual disease in acute myeloid leukemia using real-world data.
  • Analysis of de-identified data from 1457 patients treated across 14 international centers
  • Collection of clinical outcomes including treatment responses and survival from various treatment groups
  • Comparison of MRD techniques like flow cytometry and next-generation sequencing among patient groups
  • 55% of patients were male, with 68% receiving intensive chemotherapy
  • Median overall survival ranged from 5.5 to not reached across ELN risk categories
  • MRD data were available for 61% of intensively treated patients, primarily assessed by flow cytometry

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da03https://doi.org/10.1182/blood-2025-5183
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes following MRD relapse in AML patients monitored by droplet digital PCR2025
  2. 2Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries2025
  3. 3A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  4. 42025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party2025 · 56 citations
  5. 5Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?2014 · 264 citations